Modality
mRNA
MOA
BCL-2i
Target
CDK4/6
Pathway
Cell Cycle
Huntington's
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
~Jan 2021
→ ~Apr 2022
Phase 3
~Jul 2022
→ ~Oct 2023
NDA/BLA
~Jan 2024
→ ~Apr 2025
Approved
Jul 2025
→ Jul 2027
ApprovedCurrent
NCT07024869
668 pts·Huntington's
2025-07→2027-07·Completed
668 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2027-07-121.3y awayPh3 Readout· Huntington's
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3
Approved
Complet…
Catalysts
Ph3 Readout
2027-07-12 · 1.3y away
Huntington's
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07024869 | Approved | Huntington's | Completed | 668 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D |